A phase I trial of erlotinib or crizotinib in combination with the CTLA-4 inhibitor ipilimumab was conducted in patients with EGFR-mutant or ALK-rearranged NSCLC [61]. Here, CTLA4 is linked to non-small cell lung carcinoma.